Compare · ACRV vs NVO
ACRV vs NVO
Side-by-side comparison of Acrivon Therapeutics Inc. (ACRV) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ACRV and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $173.66B, about 2302.6x ACRV ($75.4M).
- Over the past year, ACRV is down 9.1% and NVO is down 28.6% - ACRV leads by 19.5 points.
- NVO has been more active in the news (4 items in the past 4 weeks vs 1 for ACRV).
- NVO has more recent analyst coverage (25 ratings vs 11 for ACRV).
- Company
- Acrivon Therapeutics Inc.
- Novo Nordisk A/S
- Price
- -
- -
- Market cap
- $75.4M
- $173.66B
- 1M return
- -3.24%
- -10.14%
- 1Y return
- -9.12%
- -28.57%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2022
- News (4w)
- 1
- 4
- Recent ratings
- 11
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest ACRV
- SEC Form 4 filed by Acrivon Therapeutics Inc.
- Chief Business Officer Levin Michaela was granted 30,000 shares (SEC Form 4)
- SEC Form 3 filed by new insider Levin Michaela
- Acrivon Therapeutics to Present at the 2026 Cantor Global Healthcare Conference
- Acrivon Therapeutics Appoints Michaela Levin, Ph.D., as Chief Business Officer
- President and CEO Blume-Jensen Peter sold $30,969 worth of shares (14,036 units at $2.21) (SEC Form 4) to satisfy withholding obligation
- Chief Legal Officer Miller Mary sold $372 worth of shares (185 units at $2.01), decreasing direct ownership by 0.23% to 82,009 units (SEC Form 4) (withholding tax)
- Chief Accounting Officer Peterson Katharine sold $203 worth of shares (101 units at $2.01), decreasing direct ownership by 0.56% to 18,033 units (SEC Form 4) (tax liability)
- Chief Development Officer Gamelin Erick sold $804 worth of shares (400 units at $2.01), decreasing direct ownership by 0.75% to 52,592 units (SEC Form 4) (for tax liability)
- Chief Operating Officer Devroe Eric sold $1,214 worth of shares (604 units at $2.01), decreasing direct ownership by 0.41% to 146,349 units (SEC Form 4) (for tax liability)
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Morgan Stanley with a new price target
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Deutsche Bank